14,5 U/mg specific activity
Advancements in Specific Activity and Biochemical Efficiency
The specific activity of a protein is a crucial measure of its effectiveness in biochemical reactions. It refers to the amount of a substance produced or converted per unit of time under specific conditions. This metric is particularly important for Neutralite Avidin, a deglycosylated form of avidin, which exhibits a near-neutral isoelectric point of 6.3, greatly reducing non-specific binding. This unique attribute, along with its high biotin-binding affinity, makes it ideal for precision assays where specificity is paramount. Additionally, its reduced molecular weight of 60 kDa enhances its solubility, boosting efficiency across various biochemical applications. The existence of Neutralite Avidin in polymerized forms (n-UltraCoat70 for lateral flow assay) further increases its binding capacity, proving beneficial in complex assays requiring heightened binding.
Elevating the Benchmark: Neutralite Avidin’s Journey to Optimal Purity and Activity
E-Proteins has been at the forefront of enhancing the quality of avidin products. From 2012 to 2014, significant investments in equipment and new technologies for avidin production led to achieving over 99% purity and more than 99.5% activity. This R&D initiative involved numerous investigations, some of which improved existing products, while others laid the groundwork for innovative derivatives.
Upon reaching maximum purity for native avidin, the focus shifted to its first derivative: Neutralite Avidin. Initially, in 1990, Neutralite Avidin had a specific activity of over 11 U/mg. The production process at that time was complex, and the specific activity was somewhat compromised by the chemical ingredients used.
In response, a new R&D program, NLA-A43, was initiated in 2015 with a simple goal: to improve specific activity. This endeavor was successful, elevating the specific activity to over 14 U/mg. In 2017, the ambitious NLA-A62 program aimed to further increase this metric to over 15.5 U/mg. This program concluded successfully in 2020.
Following these achievements, 2020 marked the beginning of another significant R&D program on Neutralite Avidin, targeting a specific activity of 16.6 U/mg, which represents the theoretical maximum for this derivative. This ongoing effort exemplifies the commitment to advancing the efficacy and versatility of Neutralite Avidin in various scientific and medical applications.
Next R&D program : A Targeted Approach to Molecular Weight Reduction